StonvexLoading…
StonvexStonvexStonvexCore line items from AMCX's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $2.31B | $2.42B | $2.71B | $3.10B |
Operating Income | $133.32M | $-39.60M | $388.41M | $86.92M |
Net Income | $89.40M | $-226.55M | $215.46M | $7.59M |
EPS (Diluted) | $1.66 | $-5.10 | $4.90 | $0.17 |
Total Assets | $3.94B | $4.36B | $4.97B | $5.63B |
Total Liabilities | $2.92B | $3.42B | $3.71B | $4.53B |
Cash & Equivalents | $502.38M | $784.65M | $570.58M | $930.00M |
Free Cash Flow OCF − CapEx | $272.37M | $330.84M | $168.71M | $137.56M |
Shares Outstanding | 56.59M | 44.44M | 43.99M | 43.73M |